{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Menzies NA"],"funding":["European Research Council","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Medical Research Council"],"pagination":["6182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10550952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission."],"journal":["Nature communications"],"pubmed_title":["Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis."],"pmcid":["PMC10550952"],"funding_grant_id":["757699","MR/W026643/1","MR/W029227/1","T32 AI007433","R01AI146555","AI007433"],"pubmed_authors":["Menzies NA","Rachow A","Cohen T","Dean AS","Dodd PJ","Schumacher SG","Nguyen LN","Mirzayev F","James LP","Knight GM","Houben RMGJ","Allwood BW","Meghji J"],"additional_accession":[]},"is_claimable":false,"name":"Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.","description":"In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2025-04-22T06:55:41.228Z","creation":"2025-02-19T01:37:30.003Z"},"accession":"S-EPMC10550952","cross_references":{"pubmed":["37794037"],"doi":["10.1038/s41467-023-41937-9"]}}